Axsome Therapeutics Inc. (AXSM) exhibits 41.0% gross margins and -21.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 7.4% implied options volatility.
Sustained 41.0% gross profitability converts into -26.1% operating margin and -21.9% ROIC, outpacing sector cost of capital.
ROIC: -21.9% // GM: 41.0%YoY revenue trajectory of +65.5% paired with -1.25% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +65.5% // FCF YLD: -1.25%Altman Z-Score of 5.34 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 5.34 // F-SCORE: 5/9Trading at 24.0x trailing P/E (35.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.4% implied move with a 0.86 put/call ratio around $141.00 max pain.
IMPL MOVE: ±7.4% // P/C: 0.86Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -28.7% net margins.
NET MARGIN: -28.7% // D/E: 1.33x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for AXSM & activate live FRED threshold breach alerts.